PDCD1 and cancer: Immune checkpoint inhibitors(ICIs) have fundamentally changed the treatment regimen and prognosisfor many cancers1−3 by providing long-term clinical responses and evencures in a subset of cancer patients.4−9 ICIs based on the antibodies against the PD-1/PD-L1 pathway arecurrently the cornerstone of this cancer immunotherapy.1,9